Status:
COMPLETED
A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh
Lead Sponsor:
Upazila Health & Family Planning Officer's (UHFPO) Office, Chakoria, Cox's Bazar
Conditions:
Ivermectin
Hydroxychloroquine
Eligibility:
All Genders
16-80 years
Brief Summary
COVID19 is a worldwide pandemic. Hence SARS-CoV-2 is a novel virus; there is no specific medication against it. Like other countries of the world, Bangladesh is also struggling in the case of treatmen...
Detailed Description
This study was done from May 2nd to June 5th, 2020. The investigators included 181 patients who were tested positive for SARS-CoV-2 infection by RT PCR presented and the sample collected at Chokoria U...
Eligibility Criteria
Inclusion
- COVID19 patients confirmed bt RT PCR at Chokoria Upazila Health Complex, Cox's Bazar; Bangladesh.
- Patients with mild to moderate degree of illness.
- Patients with normal or near-normal chest radiograph
- Patients with oxygen Saturation more than 94% who fit the outpatient treatment protocol.
Exclusion
- Patients with severe uncontrolled comorbid conditions. (Bronchial asthma, COPD exacerbation, ischemic heart disease, uncontrolled diabetes mellitus, advanced renal and hepatic disease, carcinoma, hospitalized, Immuno-compromised patients)
- BMI\>30
- Contraindication / possible drug interaction with Ivermectin and Hydroxychloroquine.
Key Trial Info
Start Date :
May 2 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 5 2020
Estimated Enrollment :
116 Patients enrolled
Trial Details
Trial ID
NCT04434144
Start Date
May 2 2020
End Date
June 5 2020
Last Update
June 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chakoria Upazilla Health Complex
Cox’s Bāzār, Bangladesh, 4741